Physician profile
Mohammad Tinawi
NPI 1770686669
$1,837.01
in general payments reported to CMS, 2019-2025
21 companies · $336 in 2025
The $336 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $12.84 · 2021: $133 · 2022: $295 · 2023: $162 · 2024: $627 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,096 · Education: $29.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,096.34 |
| Education | $29.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $308.96 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Astrazeneca Pharmaceuticals LP | $299.11 | 2019-2024 | Farxiga |
| Amgen INC. | $196.59 | 2019-2025 | Krystexxa, Tavneos |
| Vifor Pharma, INC. | $171.90 | 2019-2023 | Veltassa |
| Mallinckrodt Enterprises LLC | $131.66 | 2019 | |
| Travere Therapeutics, INC. | $106.42 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $96.60 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $75.39 | 2024-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $60.23 | 2019-2023 | Jynarque |
| Vertex Pharmaceuticals Incorporated | $52.58 | 2024 | |
| Akebia Therapeutics INC | $52.58 | 2024 | Vafseo |
| Novartis Pharmaceuticals Corporation | $45.37 | 2025 | |
| Fresenius USA Marketing, INC. | $44.44 | 2024-2025 | Velphoro, Velphoro |
| Mallinckrodt Hospital Products INC. | $38.85 | 2022 | |
| Lilly USA, LLC | $34.20 | 2025 | Jardiance |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $29.43 | 2025 | |
| Ani Pharmaceuticals, INC. | $24.87 | 2022 | |
| Glaxosmithkline, LLC. | $19.41 | 2024 | Jesduvroq |
| Ultragenyx Pharmaceutical INC. | $18.11 | 2022 | |
| Novo Nordisk INC | $16.66 | 2025 | Ozempic |
| Daiichi Sankyo INC. | $13.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Tinawi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.